AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22276957
Drug: Sonic debridement
RxNorm normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonic debridement (Sonicflex(®) 2003 L)
Trial: 22276957
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Er:YAG laser and Sonic debridement)
Trial: 17584198
Drug: Doppler Echo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doppler Echo, Doppler myocardial imaging, Strain rate imaging, transthoracic CFR after dipyridamole infusion, and brachial artery vasodilatation measurement in SSc patients
Trial: 17584198
Drug: Serological antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serological antibodies analysis
Trial: 9570235
Drug: Active Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Chinese herbal medication (CH-100), five tablets thrice daily
Trial: 9570235
Drug: Placebo tablets,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, five tablets thrice daily
Trial: 8072815
Drug: Haemophilus influenzae
RxNorm normalized name: HAEMOPHILUS INFLUENZAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently with DTPa and IPV
Trial: 3211485
Drug: 1.0% suprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% suprofen solution
Trial: 22591190
Drug: Moderate alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate alcohol dose (intended peak breath alcohol concentration of 0.04%)
Trial: 20186830
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide 130 mg/m(2) on Days 1 through 14 every 4 weeks for 12 cycles (C arm)
Trial: 20186830
Drug: Levamisole 5
RxNorm normalized name: levamisole 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole 5 mg weekly for 48 weeks (levamisole arm)
Trial: 20186830
Drug: No systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No systemic therapy (control arm)
Trial: 21218747
Drug: Intravenous omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous omeprazole
Trial: 7582397
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol treatment
Trial: 2092026
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with both amoxycillin and TDB
Trial: 25066558
Drug: Mild thrombocytopenia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild thrombocytopenia (nadir platelet count 100-149 × 10(9)/L)
Trial: 25066558
Drug: Severe thrombocytopenia
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe thrombocytopenia (nadir platelet count <100 × 10(9)/L)
Trial: 18569863
Drug: Prasugrel 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 60 mg loading dose (LD) followed by 10 days of prasugrel 10 mg MD (n = 16)
Trial: 18569863
Drug: Prasugrel 10
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10 mg MD (n = 19)
Trial: 18569863
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg MD (control)
Trial: 15779502
Drug: CODAS formulation
RxNorm normalized name: CODA-001
DrugBank: CODA-001 (DB14915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CODAS formulation of verapamil (200 mg)
Trial: 11867940
Drug: CRH administration
RxNorm normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRH administration in obese subjects
Trial: 11867940
Drug: CRH administration
RxNorm normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRH administration in control subjects
Trial: 29803203
Drug: Lactobacillus casei
RxNorm normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus casei (108 cfu daily for 8 weeks)
Trial: 29803203
Drug: Placebo (maltodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin capsules for 8 weeks)
Trial: 10442383
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy combined with pelvic radiation therapy
Trial: 7625793
Drug: Cefdinir 200
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir 200 mg
Trial: 8707743
Drug: Cefdinir 300
RxNorm normalized name: cefdinir 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefdinir 300 mg
Trial: 7625793
Drug: Cefdinir 400
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir 400 mg
Trial: 8707743
Drug: Cefdinir 600
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir 600 mg
Trial: 7625793
Drug: Cefdinir (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefdinir (all doses)
Trial: 7625793
Drug: Cefdinir (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefdinir (200 to 400 mg administered twice daily)
Trial: 2653046
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids only (Group A)
Trial: 2653046
Drug: Topical and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical and systemic corticosteroids (Group B)
Trial: 2653046
Drug: Systemic cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic cyclosporine with topical and systemic corticosteroids (Group C)
Trial: 31774581
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (inOT)
Trial: 30706652
Drug: Itopride 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride 50 mg (I50)
Trial: 30706652
Drug: Domperidone 10
RxNorm normalized name: domperidone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 10 mg (D10)
Trial: 30706652
Drug: Itopride 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride 100 mg (I100)
Trial: 26422095
Drug: Esomeprazole 5
RxNorm normalized name: esomeprazole 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 5 or 10 mg daily (<20 kg) or 10 or 20 mg daily (>20 kg) for 8 weeks
Trial: 21097785
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% micafungin (MCFG)
Trial: 21097785
Drug: Topical 0.2%
RxNorm normalized name: coal tar topical 0.2% topical soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.2% fluconazole (FCZ)
Trial: 19052139
Drug: PACAP38 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PACAP38 infusion (10 pmol/kg/min)
Trial: 19052139
Drug: PACAP38 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PACAP38 infusion
Trial: 9326194
Drug: mercaptopurine (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mercaptopurine (lower doses)
Trial: 9326194
Drug: early intensification
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: early intensification treatment
Trial: 9326194
Drug: myelosuppression during
RxNorm normalized name: Pro-C-Dure 6 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: myelosuppression during treatment
Trial: 2853091
Drug: Acebutolol (A)
DrugBank: Acebutolol (DB01193)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acebutolol (A) 400 mg once-daily
Trial: 2853091
Drug: Enalapril (E)
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril (E) 20 mg once-daily
Trial: 2853091
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Acebutolol and Enalapril (A + E)
Trial: 24200275
Drug: Myrin®-P Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myrin®-P Forte (FDC tablet containing rifampicin 150 mg, isoniazid 75 mg, ethambutol hydrochloride 275 mg, pyrazinamide 400 mg)
Trial: 24200275
Drug: Individual products
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual products in loose combination (rifampicin, isoniazid, ethambutol hydrochloride, pyrazinamide)
Trial: 21169471
Drug: Inhaled denufosol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled denufosol, 60 mg, three times daily (n = 178)
Trial: 18658109
Drug: Inhaled aztreonam
RxNorm normalized name: aztreonam Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled aztreonam lysine (AZLI) 75 mg, twice or three times daily for 28 days
Trial: 18658109
Drug: Inhaled aztreonam
RxNorm normalized name: aztreonam Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled aztreonam lysine (AZLI) 75 mg
Trial: 26971081
Drug: Sertraline 100
RxNorm normalized name: sertraline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 100 mg/day
Trial: 8957034
Drug: Low-dose ramipril
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ramipril (1.25 mg/d)
Trial: 8957034
Drug: High-dose ramipril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ramipril (5 mg/d)
Trial: 22446739
Drug: Standard support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard support with nicotine replacement therapy
Trial: 22446739
Drug: No nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No nicotine replacement therapy
Trial: 20735791
Drug: Silodosin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin (4 mg, twice daily for 4 weeks)
Trial: 20735791
Drug: Tamsulosin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.2 mg, once daily for 4 weeks)
Trial: 15702440
Drug: rhGH in
RxNorm normalized name: rhGH
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH in combination with metformin (MGH)
Trial: 15702440
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + Placebo (MP)
Trial: 12541165
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg/die
Trial: 12541165
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g/die
Trial: 1813436
Drug: 15-deoxyspergualin (DSG)
RxNorm normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-deoxyspergualin (DSG) at 3 mg/kg/day for 5 days
Trial: 1813436
Drug: 15-deoxyspergualin (DSG)
RxNorm normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-deoxyspergualin (DSG) at 5 mg/kg/day for 5 days
Trial: 1813436
Drug: 15-deoxyspergualin (DSG)
RxNorm normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-deoxyspergualin (DSG) at 7 mg/kg/day for 5 days
Trial: 1813436
Drug: 15-deoxyspergualin (DSG)
RxNorm normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-deoxyspergualin (DSG) at 3-5 mg/kg/day
Trial: 6613913
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg daily dietary aluminum (test diet)
Trial: 6613913
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg daily dietary aluminum (control diet)
Trial: 31028327
Drug: High-viscosity glass-ionomer,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-viscosity glass-ionomer, atraumatic restorative treatment method (HVGIC/ART)
Trial: 23669281
Drug: YIC (HBsAg-HBIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YIC (HBsAg-HBIG immunogenic complex therapeutic vaccine)
Trial: 19176737
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with high-dose iron-folic acid for 90 days and single-dose (500 mg) mebendazole
Trial: 19176737
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment with 100 mg mebendazole twice daily for 3 days
Trial: 19176737
Drug: 90 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 days of daily multivitamins
Trial: 19176737
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of enhanced mebendazole and multivitamins
Trial: 17971666
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg GGA t.i.d. for 2 weeks
Trial: 17971666
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg CIT b.i.d. for 2 weeks
Trial: 15600244
Drug: Antifungal agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal agents
Trial: 7627383
Drug: Octreotide (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (0.1 mg injected subcutaneously three times a day)
Trial: 7627383
Drug: Control (conservative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (conservative treatment alone)
Trial: 1790735
Drug: Ponalrestat (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponalrestat (600 mg daily)
Trial: 7041934
Drug: ibopamine (SB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibopamine (SB 7505, a new oral dopaminergic drug)
Trial: 26928164
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of suboccipital inhibitory pressure and spinal manipulation
Trial: 19618661
Drug: Cyproheptadine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproheptadine administration (n = 10)
Trial: 15002546
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of a balanced mixture of essential and non-essential amino acids at a rate of 0.1 g/kg/hour for 3 hours.
Trial: 7625114
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of trivalent cold-adapted recombinant influenza virus vaccine containing type A (H1N1 and H3N2) and B viruses.
Trial: 7625114
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of trivalent cold-adapted recombinant influenza virus vaccine.
Trial: 20170948
Drug: benazepril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benazepril (20 mg) plus amlodipine (5 mg)
Trial: 20170948
Drug: benazepril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benazepril (20 mg) plus hydrochlorothiazide (12.5 mg)
Trial: 12200762
Drug: Fiber and
RxNorm normalized name: Nutritional Supplement Oral Liquid [PEDIASURE WITH FIBER AND FOS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber and vitamin combination therapy
Trial: 7589999
Drug: omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 20 mg for 8 weeks
Trial: 7232006
Drug: Fentanyl (narcotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (narcotic analgesic)
Trial: 27314762
Drug: Aloe vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe vera (systemic juice and topical gel) for 3 months
Trial: 27314762
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of hydrocortisone and hyaluronidase with antioxidant supplements for 6 weeks and 3 months respectively
Trial: 25110231
Drug: Intravenous alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alcohol administration at two target blood alcohol concentrations (40 and 80 mg%)
Trial: 25043153
Drug: Gabapentin 300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 300 mg twice a day and dexamethasone (dex)
Trial: 12196048
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) injections of morphine every 4 hours as needed
Trial: 9484732
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (intravenous epirubicin hydrochloride: 8 doses of 40 mg/m2 each at 6-week intervals; transarterial chemotherapy: 3 courses with a maximum dose of 20 mL each at 2-month intervals)
Trial: 14987883
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant treatment (control group)
Trial: 11504165
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg once a day)
Trial: 1395119
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg b.d.)
Trial: 11309552
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg once a day)
Trial: 2505715
Drug: Combined hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hydrochlorothiazide + amiloride (50 mg + 5 mg once a day)
Trial: 2505715
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg once a day) with diuretic
Trial: 2505715
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg b.d.) with diuretic
Trial: 2505715
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg once a day) with atenolol
Trial: 2505715
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg once a day) with diuretic
Trial: 2505715
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg once a day) with beta-blocker
Trial: 2505715
Drug: Combined hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hydrochlorothiazide + amiloride (50 mg + 5 mg once a day) with beta-blocker
Trial: 1658962
Drug: Heparin-Dihydergot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-Dihydergot
Trial: 27349901
Drug: BI 811283
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 811283 (Aurora B kinase inhibitor) administered via 24‐h infusion on Days 1 and 15 of a 4‐week cycle (schedule A) or Day 1 of a 3‐week cycle (schedule B)
Trial: 27349901
Drug: BI 811283
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 811283 (Aurora B kinase inhibitor)
Trial: 18260939
Drug: Spironolactone (25-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25-75 mg/day)
Trial: 12116339
Drug: Standard ICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ICE chemotherapy
Trial: 6773727
Drug: Low-dose insulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose insulin therapy
Trial: 21616512
Drug: High-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose insulin therapy
Trial: 30333270
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of DLBS1033 (3 x 490 mg)
Trial: 30333270
Drug: Repeated administration
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated administration of DLBS1033 (3 x 490 mg/day for 3 days)
Trial: 20402381
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) monotherapy (8 mg/kg every 4 weeks)
Trial: 20191522
Drug: Methotrexate monotherapy
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate monotherapy
Trial: 18756880
Drug: Corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid therapy (5 mg Prednisolonacetate, anterior H‐inject, Winthorp) administered via parabulbar injections every day/five days
Trial: 18756880
Drug: Regular polyvitamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular polyvitamine therapy (Lutein, Beta Karoten, Vitamin E)
Trial: 1852664
Drug: Danazol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (100 mg twice daily)
Trial: 30972712
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-event patients with ≥ 180 days of warfarin exposure)